Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (510)	8/6/1999 1:56:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 579

I told you that reading it would make you ill. Definitely have mixed feelings about Comer. The company has, at times, been like an armed camp. I've had great conversations with company scientists that began from a stand of animosity. He kept the science on-track, and when things slowed down (if SIBI indicated in their statements to the press that they were not interested in any given "product" and if that extends to any given molecules discovered that had preclinical activities of interest regardless of whether or not those molecules had the spectrum of properties desirable for a drug, then something went awry with the VGCC/pain project. If not, then the Merck statements are a tad misleading, IMO. He also nurtured an environment where valuable contributors could largely be retained, and where those who left could be replaced by other good scientists. He maintained an organization that can now continue with a goal of making a positive impact on neuropharmacology. No layoffs, and now everyone can opt to become a Merck employee. That is just plain superior performance in light of management issues that have faced other neurobiotechs. But, ouch! A little additional vision in these last two years, a little less of "invented here" and a bit more of an innovative open door to the rest of the world, and the story would have been so much better for shareholders. >> It will be interesting to see how the litigation turns out. << Sigh. Yup.